Clinical Trial Update: Pragmatic Study to Optimize Neoadjuvant Treatment and Surgical De-escalation in HR+/HER2- Early Breast Cancer Using Oncotype DX and Abemaciclib [Phase 2]

View source ↗

Summary

A Phase 2 pragmatic trial in hormone receptor-positive, HER2-negative early breast cancer is testing optimized neoadjuvant therapy and potential surgical de-esc…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer
• Hormone Receptor-positive Breast Cancer

Drugs mentioned

• Abemaciclib (abemaciclib)

Snippet

Sponsor: Mario Negri Institute for Pharmacological Research | Conditions: Breast Cancer, HER2 + Breast Cancer | Phase 2 | Status: NOT_YET_RECRUITING